Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 469Neoplasms 327Colorectal Neoplasms 236Carcinoma, Non-Small-Cell Lung 233Lung Neoplasms 200Prostatic Neoplasms 179Carcinoma, Hepatocellular 173Stomach Neoplasms 138Pancreatic Neoplasms 126Leukemia, Myeloid, Acute 114Uterine Cervical Neoplasms 110Rectal Neoplasms 105Multiple Myeloma 93Recurrence 88Squamous Cell Carcinoma of Head and Neck 84Head and Neck Neoplasms 78Neoplasm Metastasis 76Ovarian Neoplasms 75Brain Neoplasms 69Colonic Neoplasms 68Glioblastoma 66Esophageal Neoplasms 66Triple Negative Breast Neoplasms 65Endometrial Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Small Cell Lung Carcinoma 54Disease 54Motor Activity 53Hematologic Neoplasms 53Glioma 46

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × Platinum-resistant Recurrent Ovarian Cancer × Clear all
NCT06509971 2024-07-19

A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

West China Second University Hospital

Phase 2 Not yet recruiting
39 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡